MicroRNA-542-3p suppresses tumor cell proliferation via targeting Smad2 inhuman osteosarcoma

Wu,Yinsheng; You,Jiongming; Li,Feng; Wang,Feng; Wang,Yong

doi:10.3892/ol.2018.8238

MicroRNA-542-3p suppresses tumor cell proliferation via targeting Smad2 inhuman osteosarcoma

Authors:
- Yinsheng Wu
- Jiongming You
- Feng Li
- Feng Wang
- Yong Wang
View Affiliations

Affiliations: Department of Orthopedic Surgery, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, Zhejiang 325000, P.R. China
Published online on: March 12, 2018 https://doi.org/10.3892/ol.2018.8238
Pages: 6895-6902
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS) is an aggressive malignant neoplasm that arises from primitive transformed cells of mesenchymal origin, and that exhibits osteoblastic differentiation and produces malignant osteoid. MicroRNA (miR)‑542‑3p has been reported to serve a crucial role in the initiation and development of several types of human cancer. However, whether miR-542-3p is involved in tumorigenesis and tumor progression of OS remains unclear. In the present study, the expression of miR‑542‑3p in OS cells and patients with OS, and its functional mechanism in OS were investigated. The data demonstrated that expression of miR‑542‑3p was significantly decreased in OS tissues and cell lines, and that restoration of miR‑542‑3p expression in OS cells inhibited cell proliferation and induced cell apoptosis. Through bioinformatics analysis and luciferase reporter assays, the present study identified that miR‑542‑3p directly targeted Smad2 mRNA and negatively regulated the expression of Smad2 at the protein level in OS cells. Furthermore, it was confirmed that OS tumor tissues with a low expression of miR‑542‑3p exhibited markedly higher Smad2 expression. Finally, through the use of gain of function and rescue experiments, the present study demonstrated that restoration of miR‑542‑3p was able to suppress the growth and proliferation of OS cells through directly targeting Smad2. To the best of our knowledge, this is the first study to demonstrate that decreased expression of miR‑542‑3p serves a role in tumor suppression in OS pathogenesis through targeting Smad2. These results will aid in elucidating the functions of miR‑542‑3p, and suggest that miR‑542‑3p may serve as a tumor suppressor gene and a promising therapeutic target of OS.

View Figures

View References

1	Luetke A, Meyers PA, Lewis A and Juergens H: Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ward E, DeSantis C, Robbins A, Kohler B and Jemal A: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 64:83–103. 2014. View Article : Google Scholar : PubMed/NCBI
3	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
4	Kleinerman E: Maximum benefit of chemotherapy for osteosarcoma achieved-what are the next steps? Lancet Oncol. 17:1340–1342. 2016. View Article : Google Scholar : PubMed/NCBI
5	Cates JM: Utility of examination of biopsy tracts in osteosarcoma resection specimens. Am J Clin Pathol. 146:324–327. 2016. View Article : Google Scholar : PubMed/NCBI
6	Wilkins RM, Cullen JW, Odom L, Jamroz BA, Cullen PM, Fink K, Peck SD, Stevens SL, Kelly CM and Camozzi AB: Superior survival in treatment of primary non-metastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol. 10:498–507. 2003. View Article : Google Scholar : PubMed/NCBI
7	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
8	Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, Todoerti K, Ronchetti D, Deliliers GL and Neri A: Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer. 48:521–531. 2009. View Article : Google Scholar : PubMed/NCBI
9	Visone R and Croce CM: MiRNAs and cancer. Am J Pathol. 174:1131–1138. 2009. View Article : Google Scholar : PubMed/NCBI
10	Cai J, Zhao J, Zhang N, Xu X, Li R, Yi Y, Fang L, Zhang L, Li M, Wu J and Zhang H: MicroRNA-542-3p suppresses tumor cell invasion via targeting AKT pathway in human astrocytoma. J Biol Chem. 290:24678–24688. 2015. View Article : Google Scholar : PubMed/NCBI
11	Althoff K, Lindner S, Odersky A, Mestdagh P, Beckers A, Karczewski S, Molenaar JJ, Bohrer A, Knauer S, Speleman F, et al: miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin. Int J Cancer. 136:1308–1320. 2015. View Article : Google Scholar : PubMed/NCBI
12	Wu W, Dang S, Feng Q, Liang J, Wang Y and Fan N: MicroRNA-542-3p inhibits the growth of hepatocellular carcinoma cells by targeting FZD7/Wnt signaling pathway. Biochem Biophys Res Commun. 482:100–105. 2017. View Article : Google Scholar : PubMed/NCBI
13	Venkatadri R, Muni T, Iyer AK, Yakisich JS and Azad N: Role of apoptosis-related miRNAs in resveratrol-induced breast cancer cell death. Cell Death Dis. 7:e21042016. View Article : Google Scholar : PubMed/NCBI
14	Long HC, Gao X, Lei CJ, Zhu B, Li L, Zeng C, Huang JB and Feng JR: miR-542-3p inhibits the growth and invasion of colorectal cancer cells through targeted regulation of cortactin. Int J Mol Med. 37:1112–1118. 2016. View Article : Google Scholar : PubMed/NCBI
15	Rang Z, Yang G, Wang YW and Cui F: miR-542-3p suppresses invasion and metastasis by targeting the proto-oncogene serine/threonine protein kinase, PIM1, in melanoma. Biochem Biophys Res Commun. 474:315–320. 2016. View Article : Google Scholar : PubMed/NCBI
16	Yoon S, Choi YC, Lee S, Jeong Y, Yoon J and Baek K: Induction of growth arrest by miR-542-3p that targets survivin. FEBS Lett. 584:4048–4052. 2010. View Article : Google Scholar : PubMed/NCBI
17	He T, Qi F, Jia L, Wang S, Song N, Guo L, Fu Y and Luo Y: MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2. J Pathol. 232:499–508. 2014. View Article : Google Scholar : PubMed/NCBI
18	Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, Kanellos I, Anastasopoulos IL, Maniou S, Karathanou K, Kalfakakou D, et al: DIANA-TarBase v7.0: Indexing more than half a million experimentally supported miRNA: mRNA interactions. Nucleic Acids Res. 43:(Database Issue). D153–D159. 2015. View Article : Google Scholar : PubMed/NCBI
19	Brown KA, Pietenpol JA and Moses HL: A tale of two proteins: Differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem. 101:9–33. 2007. View Article : Google Scholar : PubMed/NCBI
20	Bao Y, Chen Z, Guo Y, Feng Y, Li Z, Han W, Wang J, Zhao W, Jiao Y, Li K, et al: Tumor suppressor microRNA-27a in colorectal carcinogenesis and progression by targeting SGPP1 and smad2. PLoS One. 9:e1059912014. View Article : Google Scholar : PubMed/NCBI
21	Lagmay JP, Krailo MD, Dang H, Kim A, Hawkins DS, Beaty O III, Widemann BC, Zwerdling T, Bomgaars L, Langevin AM, et al: Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through children's cancer group, pediatric oncology group, and children's oncology group: Learning from the past to move forward. J Clin Oncol. 34:3031–3038. 2016. View Article : Google Scholar : PubMed/NCBI
22	Baumann S and Hennet T: Collagen accumulation in osteosarcoma cells lacking GLT25D1 collagen galactosyltransferase. J Biol Chem. 291:18514–18524. 2016. View Article : Google Scholar : PubMed/NCBI
23	Angelini A, Mavrogenis AF, Trovarelli G, Ferrari S, Picci P and Ruggieri P: Telangiectatic osteosarcoma: A review of 87 cases. J Cancer Res Clin Oncol. 142:2197–2207. 2016. View Article : Google Scholar : PubMed/NCBI
24	Buondonno I, Gazzano E, Jean SR, Audrito V, Kopecka J, Fanelli M, Salaroglio IC, Costamagna C, Roato I, Mungo E, et al: Mitochondria-targeted doxorubicin: A new therapeutic strategy against doxorubicin-resistant osteosarcoma. Mol Cancer Ther. 15:2640–2652. 2016. View Article : Google Scholar : PubMed/NCBI
25	Zhang J, Wang S, Han F, Li J, Yu L, Zhou P, Chen Z, Xue S, Dai C and Li Q: MicroRNA-542-3p suppresses cellular proliferation of bladder cancer cells through post-transcriptionally regulating survivin. Gene. 579:146–152. 2016. View Article : Google Scholar : PubMed/NCBI
26	Kureel J, Dixit M, Tyagi AM, Mansoori MN, Srivastava K, Raghuvanshi A, Maurya R, Trivedi R, Goel A and Singh D: miR-542-3p suppresses osteoblast cell proliferation and differentiation, targets BMP-7 signaling and inhibits bone formation. Cell Death Dis. 5:e10502014. View Article : Google Scholar : PubMed/NCBI
27	Massagué J: G1 cell-cycle control and cancer. Nature. 432:298–306. 2004. View Article : Google Scholar : PubMed/NCBI
28	Mishra L, Derynck R and Mishra B: Transforming growth factor-beta signaling in stem cells and cancer. Science. 310:68–71. 2005. View Article : Google Scholar : PubMed/NCBI
29	Bierie B and Moses HL: Tumour microenvironment: TGFbeta: The molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 6:506–520. 2006. View Article : Google Scholar : PubMed/NCBI
30	Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI